{"id":"W2760735711","doi":"10.1200/jco.2017.35.15_suppl.4501","title":"Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"","keywords":"Docetaxel; Medicine; Paclitaxel; Pembrolizumab; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Phases of clinical research; Cancer; Chemotherapy; Clinical trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005683064,0.001927922,0.002224243,0.0005428538,0.0004397603,0.001066028,0.001311604,0.001845624,0.009726845],"category_scores_gemma":[0.002954254,0.0005892669,0.002855273,0.0003801493,0.001103906,0.001139447,0.0006220013,0.003899495,0.00111678],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001419719,"about_ca_system_score_gemma":0.001836896,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005974068,"about_ca_topic_score_gemma":0.001155694,"domain_scores_codex":[0.9984658,0.0009269842,0.0000875847,0.00021238,0.0001179214,0.0001893599],"domain_scores_gemma":[0.9979187,0.0005904242,0.0005014336,0.0002117663,0.00009587136,0.0006818592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9649162,0.0129469,0.001263013,0.0003749988,0.0009298122,0.00006238355,0.00005798975,0.001513675,0.005498206,0.0001106726,0.001553081,0.01077322],"study_design_scores_gemma":[0.5418004,0.4422809,0.008727036,0.00003505105,0.001186646,0.0001186429,0.0000311236,0.001971202,0.001952974,0.0002706272,0.001592377,0.00003294127],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.9834585,0.001327543,0.001617835,0.0003671159,0.0001694023,0.005488555,0.005166606,0.0001400529,0.002264484],"genre_scores_gemma":[0.9813156,0.0006774396,0.00218104,0.0007740558,0.0002031792,0.006253407,0.005628662,0.00004814565,0.002918437],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.009726845,"threshold_uncertainty_score":0.03253955,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3444343944331196,"score_gpt":0.5819199167132969,"score_spread":0.2374855222801773,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}